期刊
DIGESTIVE AND LIVER DISEASE
卷 45, 期 12, 页码 1017-1021出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/j.dld.2013.06.007
关键词
Inflammatory bowel disease; Infliximab; Murine DSS colitis; Pharmacokinetic; Intestinal mucosa; Faeces; Serum levels
资金
- FONDAZIONE DI RICERCA IN MEDICINA ONLUS, Bologna, Italy
Background: Infliximab is effective in human and murine IBD, but its pharmacodynamic is still poorly known. The aim of this study was to assess the affinity of infliximab to murine TNF-alpha, its role in murine colitis when administered intra-rectally and its levels in the blood, gut mucosa and stool of healthy and sick mice. Methods: An ELISA kit was built in order to assess the affinity of infliximab to human or murine-TNF-alpha. Human IgG were used as controls. DSS model of colitis on C57BL16 mice was used to assess clinical efficacy of infliximab administered intravenously or by enema. Stool, serum and colon samples were collected to assess infliximab levels and histology for Rachmilewitz score. Results: Infliximab showed a good affinity both for human-TNF-alpha and murine-TNF-alpha. In DSS colitic mice infliximab ameliorated the severity of colitis, regardless of the administration route. In comparison with colitic mice, healthy mice displayed higher serum and mucosal infliximab levels, while detectable levels of infliximab were found in faeces, particularly in colitic mice. Conclusion: Our data support murine models to study infliximab pharmacokinetics and dynamics. Measurable levels of infliximab can be found at different concentrations in blood, intestinal mucosa and stool from healthy and sick mice, thus infliximab pharmacokinetics could have a major impact in human IBD. (C) 2013 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据